en · de · es · fr · pt
aod-9604-notes.peptides9000.com › Blog › Handling And Analytical Properties — Hands-On Walkthrough

Handling And Analytical Properties — Hands-On Walkthrough

By Editorial Desk · published 2025-11-08 · last reviewed 2025-12-14 · Blog

AOD9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-12-14. Where a claim depends on a specific study, the study is described rather than over-claimed.

Handling And Analytical Properties

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form; may appear as cake
Solubility classWater-solubleOften reconstituted in aqueous buffer
Typical storage temperature−20 °C or belowProtect from light and moisture
Typical analytical methodRP-HPLC and mass spectrometryUsed for purity and identity
Common synonymsAOD-9604; AOD9604; hGH fragment 176-191Research name and fragment description

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Related pages on this site

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Reference notes

ASP-4345, or ASP4345, is a dopamine D1 receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia. It is being developed as an adjunctive therapy for the cognitive symptoms of schizophrenia. The drug is taken orally. The most common side effects of ASP-4345 have been found to be headache and somnolence. No changes in mood or suicidality were observed. The pharmacokinetics of ASP-4345 have been studied. The median time to peak levels of ASP-4345 is 1.0 to 3.0 hours. Its mean elimination half-life is 9.1 to 26.8 hours. ASP-4345 is or was under development by Astellas Pharma. As of March 2021, no recent development has been reported. The drug has reached phase 2 clinical trials for schizophrenia. It was found to be ineffective in a phase 2 trial.

With 21 successful stolen bases in 28 attempts, it was his first season in the 20–20 club, that is, to steal 20 bases while hitting 20 home runs in the same season. Bagwell reached base 324 total times and in all but 11 games. He led the NL in doubles with 48 while earning his second All-Star selection and finishing ninth in the MVP voting. Rumors had surfaced during the 1996 season that manager Terry Collins did not get along well with Bagwell and Biggio, largely contributing to his dismissal. The Astros hired team color commentator Larry Dierker after the season to replace him. According to his autobiography, This Ain't Brain Surgery, Dierker was asked during the interview how he would handle the players. His response: "'Look, I'm tired of this Bagwell and Biggio s---,' I said. 'Bagwell and Biggio will not be a problem, believe me.' I now believe that this statement is the one that got me the job." The Astros won division titles in four of five seasons with Dierker as manager; however, in each instance, they did not advance past the first round of the playoffs, and 2001 was Dierker's last season as the club's manager.

During World War II, German Type XXI submarines (also known as "Elektroboote") were the first submarines designed to operate submerged for extended periods. Initially they were to carry hydrogen peroxide for long-term, fast air-independent propulsion, but were ultimately built with very large batteries instead. At the end of the War, the British and Soviets experimented with hydrogen peroxide/kerosene (paraffin) engines that could run surfaced and submerged. The results were not encouraging. Though the Soviet Union deployed a class of submarines with this engine type (codenamed Quebec by NATO), they were considered unsuccessful. The United States also used hydrogen peroxide in an experimental midget submarine, X-1. It was originally powered by a hydrogen peroxide/diesel engine and battery system until an explosion of her hydrogen peroxide supply on 20 May 1957. X-1 was later converted to use diesel–electric drive. Today several navies use air-independent propulsion. Notably Sweden uses Stirling technology on the Gotland-class and Södermanland-class submarines. The Stirling engine is heated by burning diesel fuel with liquid oxygen from cryogenic tanks. A newer development in air-independent propulsion is hydrogen fuel cells, first used on the German Type 212 submarine, with nine 34 kW or two 120 kW cells. Fuel cells are also used in the new Spanish S-80-class submarines although with the fuel stored as ethanol and then converted into hydrogen before use.

Sources: en.wikipedia.org

Reference notes

Pertechnetate (TcO−4) is only weakly hydrated in aqueous solutions and behaves analogously to perchlorate anion, both of which are tetrahedral. Unlike permanganate (MnO−4), it is only a weak oxidizing agent. Related to pertechnetate is technetium heptoxide. This pale-yellow, volatile solid is produced by oxidation of Tc metal and related precursors:

== Neurodegeneration == Inhibition of Hsp90 leads to Hsp70 and Hsp40 upregulation, which can channel misfolded protein for proteasome degradation, which can potentially inhibit the progression of neurodegenerative diseases. For example, Hsp70 overexpression in human neuroglioma cells transfected with mutant alpha-synuclein led to 50% less oligomeric alpha-synuclein species, pointing towards the possibility that increasing its expression could diminish the spread of Parkinson's disease. Similarly, Hsp70 overexpression suppressed poly-Q dependent aggregation and neurodegeneration in cell cultures, yeast, fly, and mouse models, and deletion of hsp70 increased the size of polyQ inclusion bodies, suggesting that increasing its expression could help to prevent Huntington's disease. Similarly, reductions in Hsp70 have been shown in transgenic mouse models of ALS and patients with sporadic ALS. Lastly, increased expression or activity of Hsp70 has been proposed as a method to prevent the progression of Alzheimer's disease, because knock down of Hsp70 promoted A-beta toxicity, and Hsp70 was shown to promote tau stability, while Hsp70 levels are decreased in tauopathies like Alzheimer's disease. Given the complex interplay between the different chaperone proteins, therapeutic development in this field is aimed at investigating how the chaperone network as a whole can be manipulated and the effect of this manipulation on the progression of neurodegenerative disease, but the balance of Hsp70 and Hsp90 levels appears to be central in this pathophysiology.

1946–1994: Christian Democracy 1994–present: National Alliance Italian People's Party The Democrats Federation of the Greens Democratic Party Northern League / League The People of Freedom The Populars of Italy Tomorrow Italia Viva Five Star Movement Brothers of Italy Independent Coalitions:

Sources: en.wikipedia.org

Reference notes

If one of the essential amino acids is not available in the required quantities, protein synthesis will be inhibited, irrespective of the availability of the other amino acids. Protein deficiency has been shown to affect all of the body's organs and many of its systems, for example affecting brain development in infants and young children; inhibiting upkeep of the immune system, increasing risk of infection; affecting gut mucosal function and permeability, thereby reducing absorption and increasing vulnerability to systemic disease; and impacting kidney function. The physical signs of protein deficiency include edema, failure to thrive in infants and children, poor musculature, dull skin, and thin and fragile hair. Biochemical changes reflecting protein deficiency include low serum albumin and low serum transferrin. The amino acids that are essential in the human diet were established in a series of experiments led by William Cumming Rose. The experiments involved elemental diets to healthy male graduate students. These diets consisted of corn starch, sucrose, butterfat without protein, corn oil, inorganic salts, the known vitamins, a large brown "candy" made of liver extract flavored with peppermint oil (to supply any unknown vitamins), and mixtures of highly purified individual amino acids. The main outcome measure was nitrogen balance. Rose noted that the symptoms of nervousness, exhaustion, and dizziness were encountered to a greater or lesser extent whenever human subjects were deprived of an essential amino acid.

In analytical chemistry, a standard solution (titrant or titrator) is a solution containing an accurately known concentration. Standard solutions are generally prepared by dissolving a solute of known mass into a solvent to a precise volume, or by diluting a solution of known concentration with more solvent. A standard solution ideally has a high degree of purity and is stable enough that the concentration can be accurately measured after a long shelf time. Making a standard solution requires great attention to detail to avoid introducing any risk of contamination that could diminish the accuracy of the concentration. For this reason, glassware with a high degree of precision such as a volumetric flask, volumetric pipette, micropipettes, and automatic pipettes are used in the preparation steps. The solvent used must also be pure and readily able to dissolve the solute into a homogenous solution. Standard solutions are used for various volumetric procedures, such as determining the concentration of solutions with an unknown concentration in titrations. The concentrations of standard solutions are normally expressed in units of moles per litre (mol/L, often abbreviated to M for molarity), moles per cubic decimetre (mol/dm3), kilomoles per cubic metre (kmol/m3), grams per milliliters (g/mL), or in terms related to those used in particular titrations (such as titres).

In 2020, Canada spent approximately $41.9 billion on domestic research and development, with supplementary estimates for 2022 at $43.2 billion. As of 2023, the country has produced 15 Nobel laureates in physics, chemistry, and medicine. The country ranks seventh in the worldwide share of articles published in scientific journals, according to the Nature Index, and is home to the headquarters of a number of global technology firms. Canada has one of the highest levels of Internet access in the world, and ranks among the most expensive countries globally for internet and mobile services.

In some countries, formalized training and minimum education standards exist for herbalists, although these are not necessarily uniform within or between countries. In Australia, for example, the self-regulated status of the profession (as of 2009) resulted in variable standards of training, and numerous loosely formed associations setting different educational standards. One 2009 review concluded that regulation of herbalists in Australia was needed to reduce the risk of interaction of herbal medicines with prescription drugs, to implement clinical guidelines and prescription of herbal products, and to assure self-regulation for protection of public health and safety. In the United Kingdom, the training of herbalists is done by state-funded universities offering Bachelor of Science degrees in herbal medicine. In the United States, according to the American Herbalist Guild, "there is currently no licensing or certification for herbalists in any state that precludes the rights of anyone to use, dispense, or recommend herbs." However, there are U.S. federal restrictions for marketing herbs as products intended to cure, mitigate, treat, or prevent disease.

Sources: en.wikipedia.org

Frequently asked questions

How should AOD-9604 be stored?

Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.

What methods confirm AOD-9604 identity?

Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.

Why can purity vary between suppliers?

Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Network